Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression.
Michele Yip-Schneider(Indiana University – Purdue University Indianapolis), Mark S. Marshall(Eli Lilly (United States)), Christopher J. Sweeney(The University of Adelaide), Darlene Barnard(Eli Lilly (United States)), Amy E. Lin(Brigham and Women's Hospital)
Cited by 68
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation
|Proceedings of the National Academy of Sciences|2014|403